Dec 13, 2023 8:00 am EST Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024
Nov 13, 2023 8:00 am EST Acasti Announces Second Quarter 2024 Financial Results and Business Highlights
Oct 4, 2023 8:00 am EDT Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)
Aug 11, 2023 7:00 am EDT Acasti Announces First Quarter 2024 Financial Results and Business Highlights
Aug 9, 2023 4:05 pm EDT Acasti to Present GTX-104 Pharmacokinetic Comparison Data at Neurocritical Care Annual Meeting
Jul 10, 2023 9:00 am EDT Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH Patients